Articles
New Arrival - Creatine for women. Shop now!
Approximately 40% of people carry an MTHFR gene variant that reduces their ability to convert synthetic folic acid into the active form their body can use. The solution is simple: take methyl-folate (5-MTHF) instead — it bypasses the conversion step entirely and works regardless of your genetic status. This article covers everything from what MTHFR is, to why mainstream advice still recommends folic acid, to whether it can cause miscarriage, to why some people feel worse on methyl-folate, to what to look for on a label.
Jump to:
By Melanie Nolan, BHSc Naturopathy | Founder, Naternal Vitamins Updated March 2026 | 7,200 words
Quick answer: Approximately 40% of people carry an MTHFR gene variant that reduces their ability to convert synthetic folic acid into the active form their body can use. The solution is simple: take methyl-folate (5-MTHF) instead — it bypasses the conversion step entirely and works regardless of your genetic status. This article covers everything from what MTHFR is, to why mainstream advice still recommends folic acid, to whether it can cause miscarriage, to why some people feel worse on methyl-folate, to what to look for on a label.
Most women arrive at the MTHFR conversation one of two ways.
The first: they've had a direct-to-consumer genetic test, seen "MTHFR C677T heterozygous" in their results, Googled it at 11pm, and fallen down a rabbit hole that is equal parts alarming and confusing. Some sites say it's catastrophic. Others say it's meaningless. Their GP, when asked, said "just take folic acid like everyone else."
The second: they've had recurrent miscarriages, or struggled to conceive, or had a pregnancy complicated by pre-eclampsia, or noticed their folate levels aren't budging despite taking their prenatal diligently. Someone — a naturopath, a forum post, a well-read friend — mentioned MTHFR as a possibility.
In both cases, the information available is either alarming or dismissive, and rarely both honest and practical at the same time.
If MTHFR prenatal vitamins in Australia are something you've started researching, this is the article that gives you the honest middle ground: what the science actually says, where reasonable practitioners disagree, what the mainstream medical bodies say and why, and what the simple, actionable conclusion is.
The MTHFR polymorphism affects approximately 40% of the global population — which means it's not a rare condition requiring specialist intervention. It's a common genetic variation that, when understood, has a straightforward clinical response. Let's work through it properly.
MTHFR stands for methylenetetrahydrofolate reductase. It's an enzyme — your body makes it from instructions in the MTHFR gene — and its job is to convert one form of folate into another.
Specifically, MTHFR converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-MTHF) — the active form of folate that your cells can actually use. This conversion is a critical step in a biochemical process called methylation, which affects everything from DNA synthesis to neurotransmitter production to how your body processes homocysteine.
The relevant variants are:
The C677T mutation is extremely common. In North America, Europe, and Australia, approximately 20–40% of white individuals are heterozygous (one copy) for MTHFR C677T, with 8–20% being homozygous (two copies). In people who are heterozygous, there is reduced enzyme function of approximately 65% of normal. In people who are homozygous, enzyme function drops to only 30% of normal.
To put that plainly: if you're homozygous for C677T, your MTHFR enzyme is working at less than a third of its intended capacity. Folic acid — which requires this enzyme to become usable — faces a significant conversion bottleneck in your body.
MTHFR A1298C is found in 7–12% of North American, European, and Australian populations. Being homozygous for A1298C leads to approximately 60% of normal enzyme function.
The A1298C variant primarily affects a different part of the methylation cycle and doesn't typically raise homocysteine levels in the same way as C677T.
Some people carry one copy of C677T and one copy of A1298C. This "compound heterozygous" status results in moderate enzyme impairment — typically less severe than homozygous C677T but more clinically significant than either single heterozygous variant alone.
People expressing MTHFR polymorphism may not experience the perceived advantage of folic acid supplementation and can be at potential risk because they are less able to transform folic acid into its active form.
In practical terms: a woman taking 800µg of folic acid daily who is homozygous for C677T is getting far less folate protection than her supplement label implies. The enzyme that should convert that folic acid is working at 30% capacity. The unconverted folic acid accumulates. Her cells don't get the active methyl-folate they need.
The solution is not complicated: give her folate in the active form that doesn't require that conversion step.
Most women don't discover their MTHFR status until genetic testing — they have no idea it's relevant because the variants are entirely asymptomatic in isolation.
But certain patterns in health history make MTHFR worth considering:
History of recurrent pregnancy loss (two or more miscarriages). The association between MTHFR and recurrent pregnancy loss is contested in the literature (see Section 9 for the honest picture), but it's one of the most common reasons women get tested and one of the most searched associations.
Persistently low folate levels on blood tests despite supplementation. In my clinic, this was the pattern I saw most often. A woman would be diligently taking her prenatal with 800µg of folic acid and return blood tests showing folate levels that hadn't budged. Sometimes what looks like poor supplementation compliance is really impaired folic acid conversion.
Elevated homocysteine. MTHFR impairment leads to reduced conversion of homocysteine to methionine, causing homocysteine to accumulate. If your blood work has flagged elevated homocysteine, MTHFR is worth investigating.
History of depression, anxiety, or poor response to antidepressants. The methylation cycle produces SAMe (S-adenosylmethionine), which is required for neurotransmitter synthesis. MTHFR impairment can reduce SAMe availability, affecting dopamine, serotonin, and noradrenaline production. There is genuine clinical evidence linking MTHFR variants with mood disorder susceptibility — see Section 10.
Strong family history of cardiovascular disease, stroke, or blood clots at a young age. Note: the current evidence does NOT support MTHFR variants alone as a meaningful cardiovascular or thrombophilia risk factor — see Sections 8 and 9 for why — but family history of these conditions sometimes prompts appropriate MTHFR investigation.
History of neural tube defect-affected pregnancy. Women with a previous NTD-affected pregnancy have higher recommended supplemental folate doses; MTHFR status is particularly relevant in this context.
Unexplained infertility or IVF failures. MTHFR variants affect oocyte maturation and embryo quality — see Section 17.
None of these alone diagnoses MTHFR. But if several apply to your history, testing is a reasonable conversation to have with your GP or naturopath.
Folate does its most time-sensitive work in the first 28 days of pregnancy — almost always before a positive test result. Neural tube closure, the process by which the foetal brain and spinal cord seal themselves, occurs in this window. The folate protection that prevents neural tube defects like spina bifida needs to already be present in your tissues when conception happens.
This is why the recommendation to start folate supplementation before conception exists — and it's why the form of folate you take matters so much. If your MTHFR enzyme is working at 30% capacity, and you're relying on folic acid to provide your neural tube protection, you may be significantly underprotected during the most critical developmental window.
When MTHFR enzyme function is reduced, homocysteine accumulates because the folate-dependent step that converts it to methionine is impaired. The normal activity of MTHFR aids in maintaining folate and methionine at constant levels, preventing homocysteine accumulation. Polymorphisms that lower enzymatic activity lead to increased plasma homocysteine, which can cause endothelial damage in blood vessels.
Elevated homocysteine in pregnancy has been associated with placental vascular dysfunction and studied in the context of pre-eclampsia. The clinical relationship is complex — see Sections 8 and 9 for the honest nuances — but maintaining adequate active folate status (which methyl-folate supplementation achieves directly) is the key protective factor regardless of how you get there.
When folic acid is consumed at doses that exceed the liver's conversion capacity, it accumulates in the bloodstream as unmetabolised folic acid (UMFA). The DHFR enzyme responsible for converting folic acid has been found to be down-regulated by an oral intake of around 200–300µg of folic acid. Most Australian prenatals contain 500–800µg — meaning the conversion capacity is routinely exceeded.
A 2024 randomised trial in the British Journal of Nutrition (Cochrane et al.) found that plasma UMFA in pregnancy was approximately 0.6 nmol/L higher in those supplementing with folic acid compared with (6S)-5-MTHF, representing roughly a 50% reduction in plasma UMFA with 5-MTHF supplementation.
The biological significance of UMFA in pregnancy remains under investigation — the researchers were appropriately cautious. But the pattern is consistent: active methyl-folate produces no UMFA; folic acid routinely does, particularly at standard prenatal doses and particularly in women with impaired MTHFR conversion.
You'll see "methylation" and "one-carbon metabolism" referenced constantly in MTHFR discussions without clear explanation. Here's the accessible version.
Methylation is the process of adding a methyl group (one carbon atom and three hydrogen atoms — CH₃) to various molecules throughout your body. This sounds abstract, but it controls:
The cycle works like this:
Folate (in its active 5-MTHF form) donates a methyl group to convert homocysteine → methionine. Methionine then becomes SAMe (S-adenosylmethionine) — the body's universal methyl donor that drives most of the methylation processes listed above.
Where MTHFR fits: The MTHFR enzyme produces 5-MTHF (the active methyl donor) from the precursor form. If MTHFR is working at 30% efficiency, the production of 5-MTHF is restricted — creating a bottleneck in the entire cycle.
The B12 connection: Vitamin B12 (specifically as methylcobalamin) is an essential cofactor in the conversion of homocysteine to methionine alongside 5-MTHF. Without adequate methylcobalamin, even optimal 5-MTHF supplementation can't complete this step efficiently. This is why MTHFR management isn't just about folate — B12 is the co-star. See Section 15.
Folic acid supplementation requires a multi-step enzymatic process before your body can use it:
Because 5-MTHF does not require activation, it is immediately available to mother and foetus and does not accumulate in blood like folic acid does in cases of reduced hepatic transformation.
Here's something most MTHFR articles don't explain: food folate is partially already in the active form.
Other forms of folate naturally occur in a reduced form in foods such as leafy green vegetables. This "natural folate" exists in a polyglutamate form, known as tetrahydrofolate (THF), and needs to be hydrolysed to a monoglutamate form by intestinal enzymes to be absorbed.
Much of the folate in food — particularly in leafy greens — is already partially reduced and partially in the 5-MTHF form. This means it bypasses some (though not all) of the MTHFR conversion steps. Food folate is not equivalent to supplemental 5-MTHF, but it is more MTHFR-friendly than synthetic folic acid. This is why eating folate-rich foods (spinach, asparagus, broccoli, lentils, egg yolks, liver) remains genuinely important even when supplementing — they provide a natural folate matrix that supports the cycle.
The catch: food folates are unstable and can be oxidised by heat, light, and metal ions, so cooking can significantly reduce bioavailability. Furthermore, food folate bioavailability is approximately 50% compared to supplemental forms. Diet alone is rarely sufficient to meet pregnancy folate requirements, particularly in the first trimester when nausea affects dietary variety.
| Feature | Folic Acid | Methyl-Folate (5-MTHF) | Food Folate |
|---|---|---|---|
| Form | Synthetic, oxidised | Active, bioavailable | Partially reduced, natural |
| Conversion required? | Yes — 4-step, MTHFR-dependent | No — immediately usable | Partial — bypasses MTHFR for some |
| Affected by MTHFR variants? | Yes — impaired at 30–65% efficiency | No — bypasses MTHFR entirely | Partially — better than folic acid |
| UMFA accumulation risk? | Yes — particularly at higher doses | No | No |
| Bioavailability | 85% (synthetic) / 100% fasted | High — direct absorption | ~50% (variable with cooking) |
| Masks B12 deficiency? | Yes — known risk | No | No |
| Works regardless of MTHFR? | Not optimally for carriers | Yes — 100% of women | Better than FA but not complete |
| NTD prevention evidence? | Extensive (decades of data) | Mechanistically clear; direct RCT evidence still developing | Observational/dietary |
| Cost to manufacture | Low | Higher | N/A |
| Found in most chemist prenatals? | Yes | Rarely at therapeutic doses | N/A |
This is the tension that confuses most women, and I want to address it directly rather than pretend it doesn't exist.
The CDC, ACOG, and Australian health authorities continue to recommend folic acid. The CDC states that folic acid is the only type of folate shown to help prevent neural tube defects, and that studies show getting 400µg of folic acid daily can increase blood folate levels regardless of MTHFR genotype. There are no clinical recommendations at this time to test for MTHFR status or to consume a different amount of folate based on MTHFR genotype.
Their position rests on:
More clinical studies are still needed to establish 5-MTHF as a safe and effective therapeutic approach comparable with folic acid for NTD prevention, and there is currently a lack of clinical trials that directly evaluate the efficacy of 5-MTHF supplementation in this context.
This is an honest and important limitation. I won't pretend it doesn't exist.
The practitioner counter-position:
The mechanistic argument for 5-MTHF over folic acid is compelling and the bioavailability evidence is strong. 5-MTHF supplementation isn't affected by MTHFR gene polymorphism, and active 5-MTHF such as Quatrefolic appears a preferred option for folate supplementation in individuals with MTHFR polymorphism. The clinical logic — give people folate in the form their bodies can use directly, bypassing the conversion bottleneck — is difficult to argue against.
Additionally, about 40–60% of the population has genetic polymorphisms that impair the conversion of supplemental folic acid to its active form, l-methylfolate. At present, it is not practical to test every woman to see if they have the relevant polymorphisms. Based on the high prevalence of these genetic polymorphisms and the importance of assuring that pregnant women get adequate supplementation, supplementation with l-methylfolate may be the best option to avoid blood folate deficiencies.
The honest synthesis:
Folic acid works at the population level. For the significant minority of women with MTHFR variants — and in the absence of a test to identify them — methyl-folate is the more conservative clinical choice. There is no downside to choosing 5-MTHF: it works for everyone regardless of MTHFR status. The argument for remaining with folic acid is predominantly institutional inertia and the absence of large direct NTD prevention trials for 5-MTHF. The argument for methyl-folate is mechanistic clarity and universal applicability.
My clinical position: choose methyl-folate. The evidence supports it; there's no evidence against it at standard doses; and for the 40% of women with MTHFR variants, it's meaningfully better.
This section matters enormously because many women have been told — by well-meaning practitioners, by alarming websites, or by misinterpretation of their own test results — that MTHFR means they have a clotting disorder and need blood thinners in pregnancy.
Here is what the major medical bodies actually say:
ACOG states: "Because of the lack of association between either heterozygosity or homozygosity for the MTHFR C677T polymorphism and any negative pregnancy outcomes, including any increased risk of VTE, screening with either MTHFR mutation analyses or fasting homocysteine levels is not recommended."
The American College of Medical Genetics states that "MTHFR polymorphism testing is frequently ordered as part of the clinical evaluation for thrombophilia. Recent meta-analyses have disproven an association between MTHFR polymorphism status and risk for venous thromboembolism. There is growing evidence that MTHFR polymorphism testing has minimal clinical utility and should not be ordered as part of a routine evaluation for thrombophilia."
ACOG's Practice Bulletin explicitly states: "MTHFR mutations by themselves do not appear to convey an increased risk of VTE in either nonpregnant or pregnant women."
The important nuance here:
The MTHFR variants themselves — absent elevated homocysteine — are not clotting risk factors. This is the current consensus of ACOG, ACMG, and the British haematology societies.
If you have MTHFR variants and elevated homocysteine, that homocysteine elevation may carry some vascular risk that is worth addressing — primarily through B12 and folate optimisation, not anticoagulation.
If you have MTHFR variants with normal homocysteine levels (which is common, especially in women who eat a reasonable diet or live in a country with folate food fortification), the clotting risk is not meaningfully elevated above background.
What does this mean practically?
If a practitioner has recommended low-molecular-weight heparin (Clexane/enoxaparin) in pregnancy based solely on MTHFR variants without elevated homocysteine or a personal history of blood clots, that recommendation is not supported by current evidence-based guidelines. Get a second opinion from a haematologist or maternal-foetal medicine specialist.
This is not a dismissal of MTHFR's importance — it's a clarification of what it specifically does and doesn't do.
This is the most anxiety-laden search query in the MTHFR space, and it deserves a direct, honest answer.
The short answer: MTHFR variants alone are not an established cause of miscarriage. The relationship is more nuanced than most websites convey.
The evidence:
Several studies have investigated the link between MTHFR polymorphisms (C677T and A1298C) and the risk of recurrent pregnancy loss. These ROC curve analyses indicated no significant differences between groups regarding C677T and A1298C expression. RPL is primarily caused by mutations in prothrombin or factor V Leiden genes.
The link between the MTHFR A1298C polymorphism and the risk of recurrent miscarriage has been the subject of numerous studies, although the results remain contentious and unclear. To reconcile these contradictory results, further research with larger, well-designed studies addressing potential sources of heterogeneity would be necessary.
What the evidence does and doesn't show:
The practical message:
If you have had recurrent pregnancy loss, MTHFR testing is reasonable — not because the variants are likely to be the primary cause, but because identifying them (and optimising folate and B12 accordingly) is one of the modifiable factors worth addressing. Testing for antiphospholipid antibodies, factor V Leiden, prothrombin G20210A, and thyroid function is also important — these are more strongly associated with RPL than MTHFR variants.
In patients with repeated miscarriages and ART failures, research has observed a strong impact for the C677T MTHFR isoform. Both partners could be responsible for the failure; it isn't restricted to women. Couples with fertility problems where at least one partner carries one of the two main MTHFR isoforms should be supplemented with 5-MTHF rather than folic acid to bypass the bottleneck created by the MTHFR deficiency.
There is a genuine clinical rationale for optimising 5-MTHF in the context of recurrent miscarriage. That's different from saying MTHFR causes miscarriage — it doesn't, in isolation. It's a modifiable factor worth addressing in a comprehensive RPL workup.
Not all methyl-folate supplements are equivalent, and understanding why matters when you're evaluating labels.
5-MTHF comes in different salt forms:
Quatrefolic is the patented glucosamine salt of 5-MTHF, developed by Gnosis by Lesaffre. Quatrefolic, the glucosamine salt of 5-MTHF, offers significant advantages over previous generations of folates. Thanks to its high solubility and bioavailability, the supplement delivers finished folate directly used by an organism without any specific form of metabolism, making it the ideal choice for everyone regardless of MTHFR polymorphism status.
The glucosamine salt form has superior water solubility and stability compared to earlier calcium salt versions — meaning it doesn't degrade as readily in the supplement capsule, and it absorbs more efficiently in the gut.
The clinical evidence for Quatrefolic specifically:
Quatrefolic at 400µg, in conjunction with B6 and B12, demonstrated the capacity to lower homocysteine serum levels better than conventional high-dose folic acid supplementation at 5mg per day — with the ideal homocysteine level reached in 55.8% of cases in the Quatrefolic group.
That's a striking finding: 400µg of Quatrefolic outperforming 5mg of folic acid — more than 12 times the dose — for homocysteine reduction. That's the difference between an active, bioavailable form and a synthetic form hitting a conversion bottleneck.
In a case series of seven couples with more than five miscarriages and a history of inefficient supplementation with high doses of folic acid (5mg/day), supplementation for four months with 400µg/day of Quatrefolic resulted in six couples achieving pregnancy.
This is a small case series, not an RCT — I'm not claiming it proves causation. But it illustrates the clinical observation that switching from high-dose folic acid to Quatrefolic 5-MTHF can produce meaningful outcomes in couples who haven't responded to folic acid supplementation.
This is exactly why I chose Quatrefolic for EverNatal — and why the dose and form both matter. Not an accident.
This is the section that most MTHFR supplement guides omit entirely. I'm including it because not including it would undermine the trust of every woman who has started methyl-folate and felt worse.
The clinical reality: A subset of people — the research doesn't give us a precise percentage, but it's clinically meaningful — experience adverse symptoms when starting methyl-folate supplementation, particularly at high doses.
Reported symptoms include:
The proposed mechanism:
The concept most often invoked is "overmethylation" — the idea that methyl-folate, by bypassing the natural conversion bottlenecks, can push the methylation cycle into overdrive, increasing SAMe levels and potentially increasing neurotransmitter activity beyond comfortable thresholds.
Too many methyl groups may upset the proper function of the body's normal biochemical processes, which may lead to symptoms like anxiety, fatigue, poor concentration, panic attacks, sleep disorders, and sensitivities to environmental toxins. However, it's important to note there is little scientific evidence that "overmethylation" is a clinical condition, as it has not been well-studied in Western medicine.
I want to be honest about this: "overmethylation" is a concept used clinically but not formally validated in Western medicine with robust RCT evidence. The symptom experiences are real — clinicians see them regularly. The exact mechanism is contested. It's likely that individual genetic variation beyond MTHFR (including COMT variants, which affect how neurotransmitters are broken down) affects methyl-folate tolerance.
What to do if you experience these symptoms:
The reassurance: At standard prenatal supplemental doses (400–500µg of Quatrefolic per day, as used in EverNatal), these reactions are uncommon. They are more typically associated with high-dose therapeutic methyl-folate supplementation (1mg+) used for specific clinical indications. The prenatal dosing range is designed for broad tolerability.
In Australia, it is illegal to have more than 500µg of folate in a listed medicine (supplement). This TGA regulation means that Australian prenatal supplements containing methyl-folate are constrained to doses that are generally well-tolerated.
Folinic acid (5-formyl-THF, also called leucovorin) is a different active folate form that is often confused with methyl-folate. It's not the same as folic acid.
Folinic acid sits upstream of 5-MTHF in the folate cycle — it's an active form that can be converted to methyl-folate but via a different pathway than folic acid requires. Crucially, this conversion doesn't require the MTHFR enzyme — which makes folinic acid MTHFR-bypassing, like 5-MTHF.
When folinic acid is preferred over methyl-folate:
Folinic acid is sometimes described as a "gentler" active folate — it feeds into the methylation cycle without the direct methyl-donor activity of 5-MTHF, which may explain why it's better tolerated by sensitive individuals.
The practical takeaway:
For most women, 5-MTHF (particularly Quatrefolic) is the clinical first choice. Folinic acid is the appropriate alternative for women who genuinely can't tolerate methyl-folate forms. Both bypass the MTHFR conversion problem. Neither is folic acid.
If you're working with a practitioner on MTHFR management and methyl-folate isn't agreeing with you, ask about folinic acid — specifically as calcium folinate or calcium leucovorin — rather than reverting to synthetic folic acid.
Yes — more than most MTHFR articles acknowledge.
As covered in Section 6, food folate is partially already in reduced/active forms, making it more MTHFR-friendly than synthetic folic acid. Much of our dietary folate is already in the active form of L-methylfolate. For this reason, MTHFR carriers should all aim to eat more folate-rich foods, particularly leafy greens and sprouted legumes.
Best food sources of natural folate:
| Food | Folate content (approximate) | Notes |
|---|---|---|
| Chicken liver | 588µg per 100g | Limit to 100g/week (vitamin A) |
| Beef liver | 290µg per 100g | Same caveat |
| Cooked lentils | 180µg per cup | Partially active form |
| Spinach (raw) | 194µg per 100g | Significant loss with cooking |
| Asparagus | 149µg per 100g | Lightly steam to preserve |
| Broccoli | 63µg per 100g | Raw or light steaming |
| Avocado | 81µg per 100g | Good bioavailability |
| Eggs (yolk) | 146µg per 6 yolks | Excellent bioavailability |
| Brussels sprouts | 61µg per 100g | Underused source |
| Edamame | 311µg per cup | Good plant source |
The cooking caveat: Food folates are unstable and can be oxidised by heat, light, and metal ions. Cooking can significantly reduce bioavailability — pre-chopping vegetables causes oxidative loss, and boiling, steaming, and microwave heating all reduce folate content. Lightly steamed or raw is preferable for folate preservation.
Can diet alone replace supplementation for MTHFR carriers?
No — not reliably. It is exceedingly difficult for most people to get the daily recommended amount of folate through food alone, particularly during pregnancy when requirements increase five-to-ten-fold compared to non-pregnant women. Dietary folate is an important addition to supplementation, not a replacement for it — particularly given the first-trimester nausea that often limits dietary variety during the most critical developmental window.
This is perhaps the most clinically underemphasised aspect of MTHFR management. Most women know to switch from folic acid to methyl-folate. Far fewer know that B12 is an essential co-star in this biochemistry.
Why B12 matters for MTHFR management:
The conversion of homocysteine to methionine — the key methylation step that both protects against homocysteine accumulation and drives SAMe production — requires both 5-MTHF (the methyl donor) and methylcobalamin (active B12, the cofactor).
Think of it as a two-key system: 5-MTHF provides the methyl group, methylcobalamin facilitates the transfer. Without adequate B12, even optimal 5-MTHF supplementation can't complete this step efficiently. Homocysteine continues to accumulate.
The form of B12 matters too:
The folic acid-B12 masking problem:
Folic acid can pose health risks in certain conditions, including cases where it will conceal megaloblastic anaemia due to vitamin B12 deficiency. This risk can be avoided by supplementation with 5-MTHF rather than folic acid, because 5-MTHF does not accumulate in blood like folic acid does in cases of reduced hepatic transformation and does not mask B12 deficiency.
This is a clinically important point: high-dose folic acid can mask the blood signs of B12 deficiency, meaning a woman can progress to neurological B12 deficiency without the usual haematological warning signs. Methyl-folate does not carry this risk.
Testing B12: If you have MTHFR variants, it's worth testing your B12 status alongside your folate. Ask for serum B12 — and if you're told it's "normal," check that it's above 300 pmol/L, not just above the lab's lower reference range. Suboptimal B12 (200–300 pmol/L) is often missed because it falls within "normal" ranges but can impair methylation function.
Plant-based women and MTHFR: The combination of plant-based diet (with no reliable dietary B12) and MTHFR variants creates a particularly significant supplementation need. Methylcobalamin at 50–100µg daily is typically required — far above what a standard prenatal delivers.
Homocysteine is an amino acid produced when methionine is broken down. In a well-functioning methylation cycle, homocysteine is efficiently converted back to methionine with the help of 5-MTHF and B12. When the cycle is impaired — through MTHFR variants, low folate, or low B12 — homocysteine accumulates.
Why homocysteine matters in pregnancy:
Elevated homocysteine (hyperhomocysteinaemia) is associated with placental vascular dysfunction and has been studied in the context of pre-eclampsia, placental abruption, and pregnancy loss. The relationship is complex and contested at the level of MTHFR variants specifically (see Sections 8–9), but elevated homocysteine itself is a more consistently agreed-upon risk marker than MTHFR genotype.
When to test homocysteine:
What the numbers mean:
Normal pregnancy homocysteine is generally considered to be below 7–8 µmol/L — levels are typically lower in pregnancy than in non-pregnant adults due to haemodilution. A result above 10 µmol/L warrants intervention; above 15 µmol/L is considered significant hyperhomocysteinaemia.
What to do with elevated homocysteine:
The primary intervention is optimising 5-MTHF and methylcobalamin supplementation. B6 (as pyridoxal-5-phosphate) is also involved in an alternative homocysteine-lowering pathway (the transsulfuration pathway) and is worth ensuring adequate intake. Quatrefolic at 400µg, with B6 and B12, demonstrated the capacity to lower homocysteine serum levels better than conventional high-dose folic acid supplementation at 5mg/day.
Homocysteine testing can be ordered through your GP. Medicare coverage depends on clinical indication; in the context of recurrent pregnancy loss or established MTHFR variants, there is usually a justifiable clinical reason.
For women undergoing IVF or experiencing unexplained infertility, MTHFR is particularly worth understanding.
Women and men with fertility problems may have low folate availability, which is often related to MTHFR enzyme polymorphism. Preconceptional folate supplementation has been linked to beneficial reproductive outcomes in both natural pregnancies and those after ART treatment. An increasing volume of publications shows that 5-MTHF is a better option than folic acid to correct metabolic defects in gametes and embryos.
A 2022 retrospective cohort study in Human Reproduction Open examined the relationship between MTHFR genotype and IVF/ICSI outcomes: women with the combined 677TT/1298AA genotype, whose enzyme activity was the lowest, had a lower oocyte maturation rate compared with those with the wild-type genotype. The oocyte maturation rate decreased linearly with the decline in MTHFR enzyme activity determined by combined C677T/A1298C genotypes.
In plain language: MTHFR variants affect egg quality and maturation — and the effect is dose-dependent on how significantly the enzyme is impaired. This is clinically relevant for women going through egg collection cycles.
Research has identified that MTHFR polymorphisms affect male fertility as well. MTHFR polymorphisms are associated with oligozoospermia and male infertility in general. Men who have polymorphisms may influence recurrent pregnancy loss irrespective of the female having the MTHFR polymorphism.
If you're going through IVF or have been told you have unexplained infertility, it is worth discussing MTHFR testing and methyl-folate optimisation with your fertility specialist or naturopath. This is one area where there's sufficient evidence to act on without waiting for further RCTs.
Yes — and this is almost never included in prenatal MTHFR guides.
MTHFR variants in men affect sperm DNA methylation and overall sperm quality. MTHFR polymorphisms in males are associated with oligozoospermia (low sperm count) and male infertility in general. Male MTHFR status may influence recurrent pregnancy loss irrespective of whether the female carries the polymorphism.
Methylation is essential for sperm chromatin compaction and DNA repair during spermatogenesis. MTHFR impairment — particularly in the context of low folate — can increase sperm DNA fragmentation, affecting fertilisation rates and embryo quality.
Practical implications for couples:
This is something I always discussed with couples in clinic. It's a fundamentally different conversation from "just the woman takes folate" — optimal methylation for conception is a both-partner project.
Testing is useful for understanding your individual picture. It's not a prerequisite for making the more sensible supplementation choice.
Here's the logic: methyl-folate works for everyone, regardless of MTHFR status. If you switch to a Quatrefolic prenatal, you've addressed the MTHFR concern entirely — without needing a result in hand. Testing confirms the picture; it doesn't change the solution.
That said, testing has value for:
Via your GP: Request MTHFR C677T and A1298C genotyping through private pathology (MPS, Sullivan Nicolaides, Laverty). This is not Medicare-funded as a standalone test; cost is typically $60–$120 out of pocket. Specify you want both variants tested.
Via a naturopath: Many integrative practitioners include MTHFR in a broader preconception pathology panel. This may be more cost-effective as part of a panel.
Direct-to-consumer genetic testing: 23andMe and AncestryDNA both test for C677T and A1298C. Results are uploaded to interpretation tools (like Genetic Genie) that contextualise MTHFR findings. These require interpretation — a naturopath or integrative GP can help you understand what your specific combination means for you.
| Genotype | What it means | Enzyme function | Clinical implication |
|---|---|---|---|
| CC/AA (no variants) | Wild type | ~100% | Folic acid converts adequately; 5-MTHF still preferable |
| CT/AA or CC/AC (heterozygous, one variant) | Mild impairment | ~65% | 5-MTHF is appropriate; monitor folate levels |
| TT/AA (homozygous C677T) | Significant impairment | ~30% | 5-MTHF strongly preferred; check homocysteine and B12 |
| CC/CC (homozygous A1298C) | Moderate impairment | ~60% | 5-MTHF appropriate; generally less symptomatic than C677T |
| CT/AC (compound heterozygous) | Moderate impairment | Variable | 5-MTHF appropriate; assess homocysteine |
| TT/AC (most significant) | Significant impairment | Lowest | 5-MTHF essential; thorough B12 and homocysteine assessment |
Look for any of these on the folate line of the supplement facts panel:
These are all active forms. They work regardless of your MTHFR status.
The Australian NRV for folate in pregnancy is 600µg DFE. For supplemental methyl-folate: 500µg of 5-MTHF per daily serve is the appropriate therapeutic range for most women.
Women with homozygous C677T or compound heterozygous status who have persistently elevated homocysteine may benefit from higher doses in consultation with their practitioner — but this is a clinical decision, not a general recommendation.
Important: In Australia, the TGA restricts listed medicines (AUST L) to a maximum of 500µg of folate per dose — making Australian prenatal supplements inherently within the well-tolerated range for 5-MTHF.
Alongside your methyl-folate, look for methylcobalamin (or adenosylcobalamin) rather than cyanocobalamin on the label. At least 25µg per daily dose is appropriate for most women; plant-based women need significantly more (50–100µg+, often requiring a standalone supplement).
EverNatal contains 500µg of Quatrefolic (levomefolate glucosamine) per two-capsule daily dose alongside active B vitamins — the formulation decision I made because the default for every pregnant woman should be the form her body can actually use.
[INTERNAL LINK: EverNatal — complete ingredient rationale and formulation notes]
[INTERNAL LINK: The complete guide to prenatal vitamin label reading]
Folate tissue stores take weeks to build. Neural tube closure occurs in the first four weeks of pregnancy — before most positive tests. Starting methyl-folate supplementation at least three months before trying to conceive ensures your stores are adequate before the most critical developmental window opens.
For women with homozygous MTHFR C677T or known low folate status: six months of preconception supplementation is more appropriate.
Continue methyl-folate through all three trimesters. While the neural tube window is the most time-critical, folate remains essential for:
The Australian RDI for folate during breastfeeding is 500µg DFE — higher than for non-pregnant women. Breast milk folate concentration reflects maternal intake. Continuing your methyl-folate prenatal through breastfeeding supports both your own methylation function (including postpartum mood stability) and your baby's continued folate supply.
MTHFR doesn't switch off at delivery. The same folate metabolism considerations that applied during pregnancy continue postpartum.
MTHFR (methylenetetrahydrofolate reductase) is an enzyme that converts folic acid into its active, usable form. Gene variants that reduce this enzyme's efficiency are extremely common: approximately 20–40% of Australian women of European background carry at least one copy of the C677T variant, with 8–20% being homozygous. An additional 7–12% carry the A1298C variant. Combined, some form of MTHFR variant affects approximately 40% of the Australian population — making it one of the most common genetic polymorphisms, not a rare or specialist condition.
Methyl-folate (5-MTHF) — specifically in the Quatrefolic form — is the clinically preferable choice for MTHFR carriers. It bypasses the conversion step that MTHFR impairs, making it immediately bioavailable regardless of your enzyme efficiency. Folic acid will still partially convert even with impaired MTHFR function, but the conversion bottleneck means you may be getting significantly less active folate than your label implies. 5-MTHF works for 100% of women; folic acid works suboptimally for the 40% who carry MTHFR variants.
In isolation, no — MTHFR variants are asymptomatic and extremely common. What matters is not the variant itself but whether folate status is adequate. A woman with homozygous C677T who is supplementing with Quatrefolic methyl-folate and eating a folate-rich diet is in an excellent nutritional position. The "seriousness" of MTHFR is about the form of supplementation, not the diagnosis — and the fix is a label change on your prenatal, not a medical intervention.
MTHFR variants don't produce symptoms directly — they affect enzyme efficiency, which becomes clinically relevant only in the context of folate status. Signs that MTHFR may be relevant include: persistently low folate levels despite supplementation, elevated homocysteine on blood work, history of recurrent miscarriage, poor response to antidepressants or a history of treatment-resistant depression, and unexplained fatigue or brain fog that doesn't respond to other interventions. None of these are diagnostic — they're signals worth investigating with a test.
Yes — with the important caveat that you switch from a folic acid-containing prenatal to one with methyl-folate (5-MTHF, preferably as Quatrefolic). A prenatal with active methyl-folate is specifically the right choice for MTHFR carriers. Most chemist-brand prenatals in Australia contain synthetic folic acid — which is the form that works suboptimally for MTHFR carriers. Checking your label and switching if necessary is the primary action.
No — this is one of the most persistent MTHFR misconceptions. Both ACOG and the American College of Medical Genetics explicitly state that MTHFR variants alone, without elevated homocysteine, are not associated with increased VTE risk or pregnancy complications from clotting. MTHFR should not be included in thrombophilia panels, and blood thinners in pregnancy are not indicated based on MTHFR status alone. If you've been advised otherwise based solely on a positive MTHFR test, ask for a referral to a haematologist for a second opinion.
MTHFR variants alone are not an established cause of miscarriage — the evidence is inconsistent and contested. Elevated homocysteine (which can result from MTHFR-impaired folate metabolism in the context of folate deficiency) has been associated with placental vascular dysfunction. The modifiable factor is not the gene variant itself but folate and B12 status. For women with recurrent pregnancy loss, MTHFR testing is worth including in a full workup — alongside more strongly associated factors like antiphospholipid antibodies, Factor V Leiden, and thyroid function — and optimising 5-MTHF and methylcobalamin is a reasonable, low-risk intervention.
Check the supplement facts panel. Look for: Quatrefolic®, levomefolate glucosamine, (6S)-5-methyltetrahydrofolic acid, L-methylfolate, 5-MTHF, or Metafolin®. These are all active methyl-folate forms. If the label says "folic acid" only, it's using the synthetic form. EverNatal uses Quatrefolic (levomefolate glucosamine) at 500µg per daily dose — the most bioavailable form of methyl-folate available in any Australian prenatal.
Testing is useful for understanding your individual picture but isn't a prerequisite for making the better supplementation choice. Methyl-folate (5-MTHF) works for everyone regardless of MTHFR status — so switching to a Quatrefolic prenatal addresses the concern whether you test or not. Test if it provides information that would change other aspects of your preconception plan (particularly if you've had miscarriages, fertility challenges, or mood disorder history). In Australia, testing is available through private pathology via GP referral for approximately $60–$120 out of pocket.
Yes. 5-MTHF has an established safety profile in pregnancy. No adverse effects have been reported in clinical trials at standard supplemental doses (400–500µg/day). Active 5-MTHF such as Quatrefolic is the preferred option for folate supplementation in individuals with MTHFR polymorphism, and its supplementation isn't affected by MTHFR gene polymorphism. In Australia, the TGA restricts listed medicine supplements to a maximum of 500µg folate per dose — ensuring prenatal doses remain within the well-tolerated range. Some individuals experience sensitivity to very high doses of methyl-folate (1mg+); this is not a concern at standard prenatal supplementation levels.
For most women, 500µg of 5-MTHF (as Quatrefolic) per daily serve meets the therapeutic range for pregnancy folate supplementation and falls within the Australian NRV recommendations. Women with homozygous C677T or significantly elevated homocysteine may benefit from higher doses under practitioner guidance — this is a clinical decision based on individual assessment rather than a general recommendation. The TGA cap of 500µg per dose in Australian listed supplements reflects appropriate dosing for the general population.
Not reliably enough to meet pregnancy requirements. Food folate is partially already in active form (better than folic acid for MTHFR carriers), but bioavailability is approximately 50% and cooking reduces it further. Pregnancy folate requirements are five-to-ten times higher than for non-pregnant women, and first-trimester nausea often limits dietary variety exactly when folate matters most. Use a methyl-folate prenatal as your foundation, and build on it with folate-rich foods — leafy greens (lightly steamed or raw), lentils, avocado, egg yolks, and asparagus are particularly good sources.
Yes — paternal MTHFR variants affect sperm DNA methylation and are associated with oligozoospermia and male infertility. Research shows that male MTHFR status can influence recurrent pregnancy loss irrespective of female MTHFR status. Both partners optimising their 5-MTHF and methylcobalamin status preconceptionally is the most complete approach — particularly for couples who have experienced recurrent pregnancy loss or are undergoing fertility treatment.
The MTHFR conversation online tends toward one of two extremes. Either it's presented as a catastrophic diagnosis requiring complex, expensive protocols — or it's dismissed entirely as a genetic variant so common it's irrelevant.
Here's the calm middle ground, which is where the evidence actually sits:
MTHFR variants are common. They reduce your ability to convert synthetic folic acid into the active form your body can use. They are not clotting disorders. They don't directly cause miscarriage. They are manageable — profoundly so — with a single formulation change.
The solution is not a complex medical protocol. It's checking the folate form on your prenatal label and switching from folic acid to methyl-folate if that's what it says. That one change gives you active, bioavailable folate that works regardless of your MTHFR status — bypassing the conversion bottleneck entirely.
I've lived this too, in my way. As a naturopath who spent years watching women supplement diligently with folic acid prenatals and return blood tests showing inadequate folate levels, the pattern eventually became impossible to ignore. Switching those women to Quatrefolic consistently moved the needle in a way that higher-dose folic acid never did.
EverNatal was formulated with 500µg of Quatrefolic (levomefolate glucosamine) as a deliberate, non-negotiable clinical decision. Not because it's the most marketable ingredient — it requires far more explanation than "folic acid" — but because it's the form that works for every woman who takes it, whether she knows her MTHFR status or not.
The standard prenatal default should be the form your body can actually use. That's all this is.
Explore EverNatal at naternalvitamins.com.au, or take our 60-second quiz. The quiz asks about your MTHFR status if you know it, your trimester, health history, and any relevant symptoms to build a personalised Naternal supplement routine — not a generic recommendation.
Melanie Nolan holds a Bachelor of Health Science (Naturopathy) and is the founder of Naternal Vitamins. All research citations are available in full text on PubMed. This article reflects the evidence base as of March 2026 and is reviewed quarterly. For personalised advice regarding MTHFR, folate dosing, and pregnancy supplementation, consult a qualified naturopath, integrative GP, or genetic counsellor.
10 min read
10 min read
Published research suggests iron bisglycinate is the best-tolerated form of iron during pregnancy. Studies show it may support iron status comparably to ferrous sulfate at roughly half the dose, with significantly fewer gastrointestinal side effects. Most pharmacy-shelf iron supplements in Australia use ferrous sulfate or ferrous fumarate — cheaper forms that commonly cause constipation and nausea.
